Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. We previously reported that pemafibrate significantly improves liver function, serum triglyceride (TG) levels and liver stiffness in non-alcoholic fatty liver disease patients, however the influence of alcohol consumption was not considered. Therefore, we explored pemafibrate efficacy in patients with steatotic liver disease (SLD) and alcohol-associated liver disease (ALD).

中文翻译：

---

一年培马贝特治疗脂肪肝的有效性：饮酒的影响。

Pemafibrate 是一种选择性过氧化物酶体增殖物激活受体 α 调节剂，可改善血脂异常患者的血清丙氨酸氨基转移酶 (ALT)。我们之前报道，培马贝特显着改善非酒精性脂肪肝患者的肝功能、血清甘油三酯（TG）水平和肝脏硬度，但没有考虑饮酒的影响。因此，我们探讨了 pemafibrate 对脂肪变性肝病 (SLD) 和酒精相关性肝病 (ALD) 患者的疗效。